The study looks at two common hand conditions that cause pain and loss of movement: rheumatoid arthritis, an autoimmune disease that inflames joints, and digital osteoarthritis, a wear‑and‑tear arthritis that affects the finger joints. A new imaging agent called 99mTc NTP15-5 will be used to help doctors see which joints are diseased. The agent is given by a small intravenous infusion, which means it is injected into a vein, and then special pictures of the hands are taken.
The purpose of the study is to find out how well this agent can identify abnormal hand joints in each condition. After the infusion, participants will have a short imaging session where a camera detects the agent inside the joints, creating what is known as scintigraphic imaging. The resulting images are reviewed by experts who do not know the participant’s diagnosis, so the assessment is unbiased. The whole process usually involves one visit for the injection and imaging, followed by a brief check‑in to record any side effects within the next week.
In this context, nuclear medicine refers to a medical field that uses tiny amounts of radioactive material to create pictures of how organs and tissues are working. The “tracer” in the agent lights up areas where the joints are inflamed, making them visible on the images. Safety is closely monitored, and any discomfort or reaction after the infusion is recorded and evaluated by the study team.
France 
